Trial Profile
Study of elevations of serum creatine kinase among HIV-positive individuals receiving dolutegravir-based therapy versus non-integrase inhibitor-based therapy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 30 Aug 2018
Price :
$35
*
At a glance
- Drugs Dolutegravir (Primary)
- Indications HIV infections
- Focus Adverse reactions
- 30 Aug 2018 New trial record
- 27 Jul 2018 Results presented at the 22nd International AIDS Conference